Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%

Bp Consulting, Inc166 enrolled

Overview

To compare bromfenac 0.09%, diclofenac sodium 0.1%, and ketorolac tromethamine 0.5% ophthalmic solutions for the treatment of acute pseudophakic CME after cataract surgery.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

166

Conditions

Acute Pseudophakic Cystoid Macular Edema

Interventions

BromfenacDRUG

1 drop (in the eye) Instill one drop in the affected eye twice daily for three months

KetorolacDRUG

1 drop (in the eye) Instill one drop in the affected eye four times daily for three months

DiclofenacDRUG

1 drop (in the eye) Instill one drop in the affected eye four times daily for three months

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients must be diagnosed with acute pseudophakic CME within 12 months of cataract surgery * Males and females 18 years and older * Able to provide written informed consent Exclusion Criteria: * Complicated cataract surgery, particularly posterior capsule rupture and vitreous loss * Pre-Existing macular pathology, including macular edema, macular scar, macular hole, or macular pucker * History of Uveitis * Ipsilateral intraocular surgery prior to cataract surgery * CME greater than one year duration

Locations (1)

Soll Eye Associates

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

Acute Pseudophakic Cystoid Macular Edema

Time frame: 5 months

Secondary Outcomes

Visual Acuity

Time frame: 5 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.